In this study the authors conducted a prospective trial of BRAF and MEK targeted therapy in advanced, operable BRAF mutation-positive melanoma to determine feasibility, tumor response rates and biomarkers of response and resistance.

READ FULL ARTICLE Curated publisher From Mdlinx